VERAVAS, Inc. is pioneering advancements in laboratory diagnostics through its proprietary VeraBIND™ technology, which addresses significant challenges in early disease detection. This innovative platform is designed to transform complex biological samples into matrix-free samples, thereby enhancing the performance of existing diagnostic tests. Key features of VeraBIND technology include uniform size magnetic nanobeads that improve reproducibility and binding capacity, a hydrophilic surface layer that minimizes non-specific binding, and rapid magnetic separation that streamlines laboratory processes. These attributes collectively contribute to improved assay accuracy, enabling the reliable detection of low-abundance biomarkers critical for early disease identification.

One of the notable applications of VeraBIND technology is the VeraBIND Tau assay, which focuses on the early detection of tau pathology associated with Alzheimer’s disease. By effectively eliminating interferences from plasma samples and purifying biomarkers such as hyperphosphorylated tau, this assay provides a more accurate and sensitive diagnostic approach. Additionally, VeraBIND technology supports a wide range of established assays and detection methods, including ELISA and mass spectrometry, making it a versatile tool for researchers and healthcare professionals. Overall, VERAVAS, Inc. is setting new standards in biomarker enrichment and early disease detection, significantly enhancing clinical diagnostics and research capabilities.

United States

Veravas is transforming laboratory diagnostics through its proprietary VeraBIND™ technology that makes early disease detection possible in any sample type. Through VeraBIND, Veravas is bringing greater patient access to high-value diagnostic tests for neurodegenerative disorders that have not been previously possible. To learn more about our technologies and clinical applications, visit veravas.com.

VERAVAS, Inc.

Company Details